An engineered probiotic Escherichia coli Nissle 1917 has shown promising results in mouse tumor models by increasing L-arginine concentrations, enhancing the number of tumor-infiltrating T cells, and synergistically working with PD-L1 blocking antibodies to clear tumors. This evidence concerns the gene CD274 and neoplasm.